Predicting Immunotherapy Response in Hepatocellular Carcinoma: A Novel Classifier Based on Cancer Stem Cells

Despite the significant advances made in the treatment of hepatocellular carcinoma (HCC) through immunotherapy, the absence of reliable biomarkers for predicting patients' response to this therapy has remained a challenge. One of the factors closely associated with the oncogenesis, invasion, metastasis, and drug resistance of HCC is cancer stem cells (CSCs). This study aimed to create a novel classifier that is related to CSCs to forecast the response of HCC patients to immunotherapy.